Overall, these observations suggest that TRP metabolism underlays IBD pathogenesis and that changes in the microbiota composition may contribute to disease development, either by influencing AhR ligand levels or by modulating the host IDO and TPH1 activity. This evidence concerns the gene AHR and irritable bowel syndrome.